UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 6-K
________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2023
Commission File Number: 001-38281
________________________
PHAXIAM Therapeutics S.A.
(Translation of registrant’s name into English)
________________________
60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F S Form 40-F £
INCORPORATION BY REFERENCE
This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-248953 and 333-259690) and registration statements on Form S-8 (File Nos. 333-222673, 333-232670, 333-239429, 333-255900 and 333-265927), of PHAXIAM Therapeutics S.A. (f/k/a ERYTECH Pharma S.A., “PHAXIAM” or the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Press Release dated September 5, 2023
On September 5, 2023, PHAXIAM Therapeutics S.A. issued a press release to provide its cash position as of June 30, 2023, and its financial calendar for the second half of 2023.
The full text of the press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.
EXHIBIT INDEX
| Exhibit | Description | |||||||
| 99.1 | Press Release dated September 5, 2023. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PHAXIAM Therapeutics S.A. | ||||||||||||||||||||
Date: | September 7, 2023 | By: | /s/ Eric Soyer | |||||||||||||||||
Name Eric Soyer | ||||||||||||||||||||
Title: Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer | ||||||||||||||||||||
Exhibit 99.1
 | PRESS RELEASE | ||||
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
Lyon (France) and Cambridge (MA, US), September 5, 2023 – 10:05 p.m. CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) (the "Company"), today publishes its cash position as of June 30, 2023, and its financial calendar for the second half of 2023.
Cash position as of June 30, 2023
As of June 30, 2023, PHAXIAM Therapeutics had cash and cash equivalents totaling €25.2 million (approximately $27.5 million).
New financial publication dates for the second half of 2023
•Update on business and key financial data for 2nd quarter and 1st half 2023: September 21, 2023 (after US market close), followed by a conference call and webcast on September 25, 2023 (2:30 pm CET/8:30 am ET).
•Update on business and key financial data for Q3 2023: November 14, 2023 (after US market close), followed by a conference call and webcast on November 15, 2023 (2:30 pm CET/8:30 am ET).
Upcoming investor conferences
To meet the Company's management at one of the conferences below, please contact the organizer or PHAXIAM Therapeutics directly (investors@phaxiam.com).
H.C. Wainwright BioConnect
Event link
•Dates: Monday, September 11 - Thursday September 14, 2023
•Place: New York
•Participants: Thibaut du Fayet (CEO), Eric Soyer (COO & CFO), Pascal Birman (CMO)
Portzamparc BPN Paribas Biotech & Health Seminar
•Dates: Wednesday, October 4 - Thursday, October 5, 2023
•Digital format with a presentation on Tuesday October 5 from 2:30 to 3:15 pm
•Participants: Thibaut du Fayet, Eric Soyer
Investor Access Event
Event link
•Dates: Monday, October 9 - Tuesday, October 10, 2023
•Place: Paris
•Participants: Thibaut du Fayet, Eric Soyer
| PRESS RELEASE | ||||
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.erytech.com
Contacts
PHAXIAM Eric Soyer COO & CFO +33 4 78 74 44 38 investors@phaxiam.com | NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor Relations Arthur Rouillé Media Relation +33 1 44 71 94 9 phaxiam@newcap.eu | ||||